Softwr

Healthcare · head to head

Allscripts TouchWorks vs Paige

Allscripts TouchWorks logo

Allscripts TouchWorks

Healthcare

Cloud-based EHR and practice management for ambulatory care

From
$200/month
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Allscripts TouchWorks allscripts moved its products to the Veradigm brand in 2022, so the Allscripts name is retired; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Allscripts TouchWorks covers Electronic Health Records, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Allscripts TouchWorks and Paige actually diverge.

Attributes where Allscripts TouchWorks and Paige differ
AttributeAllscripts TouchWorksPaige
Starting price$200/monthOn request
Pricing modelsubscriptionquote
PlatformsWeb, MobileWeb, Cloud, On-premise
Founded1986Unknown

Identical on both: free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Allscripts TouchWorks

  • Electronic Health Records
  • Practice Management
  • ePrescribing
  • Patient Portal
  • Scheduling
  • Revenue Cycle Management
  • HL7
  • FHIR

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Allscripts TouchWorks

  • Patient Carenot Paige
  • Medical Recordsnot Paige
  • Practice Managementnot Paige
  • Telehealthnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Allscripts TouchWorks
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Allscripts TouchWorks
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Allscripts TouchWorks
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Allscripts TouchWorks

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Allscripts TouchWorks

  • Allscripts moved its products to the Veradigm brand in 2022, so the Allscripts name is retired
  • Pricing is not published
  • TouchWorks is not named on the Veradigm site, so whether it survives as a distinct product cannot be confirmed from the vendor

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Allscripts TouchWorks

$200/month

No published plan breakdown. See the Allscripts TouchWorks review.

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Allscripts TouchWorks if

  • You need electronic health records.
  • You work on Web, Mobile.
  • You also want practice management.
Allscripts TouchWorks review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Allscripts TouchWorks or Paige better?
Neither clearly leads. Allscripts TouchWorks starts at $200/month and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Allscripts TouchWorks or Paige?
Allscripts TouchWorks starts at $200/month and Paige at On request.
Does Allscripts TouchWorks or Paige run on more platforms?
Allscripts TouchWorks runs on Web, Mobile. Paige runs on Web, Cloud, On-premise.
What is Allscripts TouchWorks best used for?
Allscripts TouchWorks is most often used for patient care, medical records, practice management, telehealth. Of those, patient care and medical records are not what Paige is typically brought in for.
What can Allscripts TouchWorks do that Paige cannot?
Allscripts TouchWorks covers Electronic Health Records, Practice Management, ePrescribing, Patient Portal. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Allscripts TouchWorks: How is Allscripts TouchWorks priced?

Pricing is not published on Veradigm's website. Costs are customized based on practice size, feature requirements, and deployment preferences.

Source
Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Allscripts TouchWorks: How do I get pricing and request a demo for TouchWorks?

Contact a Veradigm Account Executive or use the 'Get Demo' button on their website to discuss pricing, trial programs, and implementation.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Allscripts TouchWorks: What market segments does Veradigm serve?

Veradigm serves healthcare providers with EHR and practice management solutions, life sciences companies, and health plans/payers with risk adjustment and quality analytics.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Allscripts TouchWorks

More on Paige

Keep looking

Other head to heads